Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CTH | P32929 | 1/20 | 0.37 |
| ▸ | CBS | P35520 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28841425 | 0.96 | TSHR (0.34) | TSHRCTHCBSTHPOGABRP | |
| SCHEMBL29102071 | 0.96 | TSHR (0.34) | TSHRCTHCBSTHPOGABRP | |
| SCHEMBL1513790 | 0.84 | — | — | |
| SCHEMBL28841424 | 0.82 | CTH (0.34) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL29102070 | 0.80 | CTH (0.33) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL223598 | 0.80 | TSHR (0.33) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL19025406 | 0.79 | PAM (0.32) | TSHRCTHCBSTHPOALDH1A1 | |
| SCHEMBL19025262 | 0.78 | LMNA (0.46) | TSHRCTHCBSTHPOGABRP | |
| SCHEMBL5397637 | 0.78 | TSHR (0.32) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL303917 | 0.77 | CTH (0.36) | TSHRCTHCBSTHPOGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612619-B2 | Compositions and methods for improved gene editing | UNIVERSITY OF MASSACHUSETTS (US) | 2026-04-28 | — | — | US | claimed |
| EP-4724471-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | claimed |
| WO-2024252366-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | claimed |
| US-20240309396-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | UNIV MASSACHUSETTS (US) | 2024-09-19 | — | — | US | claimed |
| US-20240124870-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | UNIVERSITY OF MASSACHUSETTS | 2024-04-18 | — | — | US | claimed |
| WO-2023015205-A2 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | UNIVERSITY OF MASSACHUSETTS (US) | 2023-02-09 | — | — | WO | claimed |
| US-20220348912-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | UNIV MASSACHUSETTS (US) | 2022-11-03 | — | — | US | claimed |
| EP-3781677-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | University of Massachusetts (US) | 2021-02-24 | — | — | EP | claimed |
| US-20190345479-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | UNIVERSITY OF MASSACHUSETTS | 2019-11-14 | — | — | US | claimed |
| WO-2019204226-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | UNIVERSITY OF MASSACHUSETTS (US) | 2019-10-24 | — | — | WO | claimed |
| US-9616102-B2 | Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-11 | — | — | US | claimed |
| US-9061071-B2 | Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-23 | — | — | US | claimed |
| EP-1673113-B1 | IMPLANTS WITH ATTACHED SILYLATED THERAPEUTIC AGENTS | SMART TECH LP (US) | 2010-12-29 | — | — | EP | claimed |
| CN-122070365-A | Systems and compositions comprising highly active trans-amplified replicase | 百欧恩泰欧洲股份公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12612619-B2 | Compositions and methods for improved gene editing | UNIVERSITY OF MASSACHUSETTS (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4724610-A2 | HIGH THROUGHPUT SCREEN FOR GENETIC VARIANTS ASSOCIATED WITH SHORT STATURE | BioMarin Pharmaceutical Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-1105409-A2 | PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000069911-A1 | LONG LASTING INSULINOTROPIC PEPTIDES | CONJUCHEM, INC. (CA) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000070665-A2 | LONG LASTING ANTI-ANGIOGENIC PEPTIDES | CONJUCHEM, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069900-A2 | PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612619-B2 | Compositions and methods for improved gene editing | ALKBH2, ALKBH1, ALKBH3 | TSHR 2302/4885CTH 1358/4885CBS 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.